In Vitro Drug Release Testing and In Vivo/In Vitro Correlation for Long Acting Implants and Injections

Part of the Advances in Delivery Science and Technology book series (ADST)


An advantage of long acting implants and injections is their ability to maintain a relatively constant drug concentration at the site of interest. In vitro drug release testing, particularly where an in vivo/in vitro relationship has been established, can help in ensuring in vivo performance. There are various in vitro release testing methods, which are chosen, based on availability, dosage form specifications and drug properties. These are categorized into three groups: sample and separate, flow-through and dialysis. Although there are currently no standard methods for in vitro release testing of controlled release parenterals, standard dissolution apparatus specified by the United States Pharmacopeia have been adapted in some cases and the development of compendial monographs is anticipated. An in vivo/in vitro correlation can predict the bioavailability characteristics of a product based on release in vitro.


  1. 1.
    Adeyeye CM, Price JC (1994) Development and evaluation of sustained-release ibuprofen-wax microspheres. II. In vitro dissolution studies. Pharm Res 11(4):575–579PubMedGoogle Scholar
  2. 2.
    D’Souza SS, DeLuca PP (2005) Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech 6(2):E323–E328PubMedGoogle Scholar
  3. 3.
    Ghaly ES, Sepulveda S (1996) In-vitro evaluation of sustained release ibuprofen microspheres. P R Health Sci J 15(2):97–100PubMedGoogle Scholar
  4. 4.
    Hickey T, Kreutzer D, Burgess DJ, Moussy F (2002) Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 23(7):1649–1656PubMedGoogle Scholar
  5. 5.
    Lindberg NO, Persson CG (1972) In vitro and in vivo evaluation of sustained release tablets containing norephedrine chloride. Acta Pharm Suec 9(3):237–248PubMedGoogle Scholar
  6. 6.
    Nakajima T, Takashima Y, Iida K, Mitsuta H, Koishi M (1987) Preparation and in vitro evaluation of sustained-release suppositories containing microencapsulated indomethacin. Chem Pharm Bull (Tokyo) 35(3):1201–1206Google Scholar
  7. 7.
    Schneid TR (1992) An in vitro analysis of a sustained release system for the treatment of denture stomatitis. Spec Care Dentist 12(6):245–250PubMedGoogle Scholar
  8. 8.
    Wada R, Hyon SH, Nakamura T, Ikada Y (1991) In vitro evaluation of sustained drug release from biodegradable elastomer. Pharm Res 8(10):1292–1296PubMedGoogle Scholar
  9. 9.
    Waters LJ, Pavlakis E (2007) In vitro controlled drug release from loaded microspheres–dose regulation through formulation. J Pharm Pharm Sci 10(4):464–472PubMedGoogle Scholar
  10. 10.
    Yang TT, Swarbrick J (1986) Sustained-release delivery systems, II: in vitro dissolution of 4,4′-sulfonylbisbenzamine (dapsone)–N-dodecanoyl-4,4′-sulfonylbisbenzamine comelts. J Pharm Sci 75(3):264–270PubMedGoogle Scholar
  11. 11.
    De Souza EB, Zaczek R, Culp S, Appel NM, Contrera JF (1991) Comparison of the effects of repeated oral versus subcutaneous fenfluramine administration on rat brain monoamine neurons: pharmacokinetic and dose-response data. Pharmacol Biochem Behav 39(4):963–969PubMedGoogle Scholar
  12. 12.
    Konsue N, Kirkpatrick J, Kuhnert N, King LJ, Ioannides C (2010) Repeated oral administration modulates the pharmacokinetic behavior of the chemopreventive agent phenethyl isothiocyanate in rats. Mol Nutr Food Res 54(3):426–432PubMedGoogle Scholar
  13. 13.
    Rainsford KD, Stetsko PI, Sirko SP, Debski S (2003) Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease. J Pharm Pharmacol 55(5):661–668PubMedGoogle Scholar
  14. 14.
    Thoren MC, Wivall-Helleryd IL, Blum WF, Hall KE (1994) Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol 131(1):33–40PubMedGoogle Scholar
  15. 15.
    Patil SD, Papadimitrakopoulos F, Burgess DJ (2004) Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol Ther 6(6):887–897PubMedGoogle Scholar
  16. 16.
    Abrahamsson B, Alpsten M, Bake B, Jonsson UE, Eriksson-Lepkowska M, Larsson A (1998) Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food. J Control Release 52(3):301–310PubMedGoogle Scholar
  17. 17.
    Okimoto K, Miyake M, Ohnishi N, Rajewski RA, Stella VJ, Irie T, Uekama K (1998) Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)7m-beta-CD. Pharm Res 15(10):1562–1568PubMedGoogle Scholar
  18. 18.
    Okimoto K, Rajewski RA, Stella VJ (1999) Release of testosterone from an osmotic pump tablet utilizing (SBE)7m-beta-cyclodextrin as both a solubilizing and an osmotic pump agent. J Control Release 58(1):29–38PubMedGoogle Scholar
  19. 19.
    Pope DG, Wilkinson PK, Egerton JR, Conroy J (1985) Oral controlled-release delivery of ivermectin in cattle via an osmotic pump. J Pharm Sci 74(10):1108–1110PubMedGoogle Scholar
  20. 20.
    Rani M, Surana R, Sankar C, Mishra B (2003) Development and biopharmaceutical evaluation of osmotic pump tablets for controlled delivery of diclofenac sodium. Acta Pharm 53(4):263–273PubMedGoogle Scholar
  21. 21.
    Theeuwes F, Swanson D, Wong P, Bonsen P, Place V, Heimlich K, Kwan KC (1983) Elementary osmotic pump for indomethacin. J Pharm Sci 72(3):253–258PubMedGoogle Scholar
  22. 22.
    Gao P, Xu H, Ding P, Gao Q, Sun J, Chen D (2007) Controlled release of huperzine A from biodegradable microspheres: in vitro and in vivo studies. Int J Pharm 330(1–2):1–5PubMedGoogle Scholar
  23. 23.
    Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ (2007) Controlling acute inflammation with fast releasing dexamethasone-PLGA microsphere/pva hydrogel composites for implantable devices. J Diabetes Sci Technol 1(1):8–17PubMedGoogle Scholar
  24. 24.
    Bonny JD, Kyowa M (1995) Use of in vitro release tests for the prediction of the in vivo behavior and the development of flucytosine controlled-release capsules. J Pharm Sci 84(5):619–623PubMedGoogle Scholar
  25. 25.
    Brock MH, Dansereau RJ, Patel VS (1994) Use of in vitro and in vivo data in the design, development, and quality control of sustained-release decongestant dosage forms. Pharmacotherapy 14(4):430–437PubMedGoogle Scholar
  26. 26.
    Khidr SH, Niazy EM, el-Sayed YM (1998) Development and in-vitro evaluation of sustained-release meclofenamic acid microspheres. J Microencapsul 15(2):153–162PubMedGoogle Scholar
  27. 27.
    Wu LS, McCormick TJ, Chang RK, Pang J, McCummings T, Ramos M, Hussain MA (1999) Development of an unconventional in vitro drug release test method for a bile acid sequestrant, DMP 504, tablet. Pharm Res 16(7):1136–1139PubMedGoogle Scholar
  28. 28.
    Zhang L, Parsons DL, Navarre C, Kompella UB (2002) Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 85(1–3):73–81PubMedGoogle Scholar
  29. 29.
    Malinowski HJ (1997) The role of in vitro-in vivo correlations (IVIVC) to regulatory agencies. Adv Exp Med Biol 423:261–268PubMedGoogle Scholar
  30. 30.
    FDA (1997) Bioavailability and bioequivalence studies for orally administered drug products – general considerations. Food and Drug Administration Center for Drug Evaluation and Research Guidance for IndustryGoogle Scholar
  31. 31.
    FDA (1997c) Extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlationsGoogle Scholar
  32. 32.
    Brown CK, Chokshi HP, Nickerson B, Reed RA, Rohrs BR, Shah PA (2004) Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharmaceut Tech 28(12):56–65Google Scholar
  33. 33.
    Klose D, Delplace C, Siepmann J (2011) Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles. Int J Pharm 404(1–2):75–82PubMedGoogle Scholar
  34. 34.
    Guy RH, Hadgraft J (1981) Theoretical comparison of release rates of drugs into sink and nonsink conditions. J Pharm Sci 70(11):1243–1245PubMedGoogle Scholar
  35. 35.
    Gupta KC, Ravi Kumar MN (2001) pH dependent hydrolysis and drug release behavior of chitosan/poly(ethylene glycol) polymer network microspheres. J Mater Sci Mater Med 12(9):753–759PubMedGoogle Scholar
  36. 36.
    Kim H, Burgess DJ (2002) Effect of drug stability on the analysis of release data from controlled release microspheres. J Microencapsul 19(5):631–640PubMedGoogle Scholar
  37. 37.
    Voisine JM, Zolnik BS, Burgess DJ (2008) In situ fiber optic method for long-term in vitro release testing of microspheres. Int J Pharm 356(1–2):206–211PubMedGoogle Scholar
  38. 38.
    Burgess DJ, Crommelin DJ, Hussain AS, Chen ML (2004) Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS J 6(1):100–111PubMedGoogle Scholar
  39. 39.
    Burgess DJ, Hussain AS, Ingallinera TS, Chen ML (2002) Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP. Pharm Res 19(11):1761–1768PubMedGoogle Scholar
  40. 40.
    Martinez MN, Rathbone MJ, Burgess D, Huynh M (2010) Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products. J Control Release 142(1):2–7PubMedGoogle Scholar
  41. 41.
    Collier JW, Thakare M, Garner ST, Israel B, Ahmed H, Granade S, Strong DL, Price JC, Capomacchia AC (2009) Accelerated dissolution testing for controlled release microspheres using the flow-through dissolution apparatus. Pharm Dev Technol 14(1):9–17PubMedGoogle Scholar
  42. 42.
    D’Souza SS, Faraj JA, DeLuca PP (2005) A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres. AAPS PharmSciTech 6(4):E553–E564PubMedGoogle Scholar
  43. 43.
    Shameem M, Lee H, DeLuca PP (1999) A short term (accelerated release) approach to evaluate peptide release from PLGA depot-formulations. AAPS PharmSci 1(3):E7PubMedGoogle Scholar
  44. 44.
    Wang Y, Lapitsky Y, Kang CE, Shoichet MS (2009) Accelerated release of a sparingly soluble drug from an injectable hyaluronan-methylcellulose hydrogel. J Control Release 140(3):218–223PubMedGoogle Scholar
  45. 45.
    Crail DJ, Tunis A, Dansereau R (2004) Is the use of a 200 ml vessel suitable for dissolution of low dose drug products? Int J Pharm 269(1):203–209PubMedGoogle Scholar
  46. 46.
    Cupera J, Lansky P (2010) Random effects in drug dissolution. Eur J Pharm Sci 41(3–4):430–439PubMedGoogle Scholar
  47. 47.
    Gao Z, Ahadi S, Moore TW, Doub WH, Westenberger BJ, Buhse LF (2010) Effects of vessel geometric irregularity on dissolution test results. J Pharm Sci 100(3):1093–1101PubMedGoogle Scholar
  48. 48.
    Bhardwaj U, Burgess DJ (2010) A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm 388(1–2):287–294PubMedGoogle Scholar
  49. 49.
    Iyer SS, Barr WH, Karnes HT (2007) A ‘biorelevant’ approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant. Int J Pharm 340(1–2):119–125PubMedGoogle Scholar
  50. 50.
    Rawat A, Burgess DJ (2011) USP apparatus 4 method for in vitro release testing of protein loaded microspheres. Int J Pharm 409(1–2):178–184PubMedGoogle Scholar
  51. 51.
    Bain DF, Munday DL, Smith A (1999) Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(dl-lactide). J Microencapsul 16(3):369–385PubMedGoogle Scholar
  52. 52.
    Deng X, Zhou S, Li X, Zhao J, Yuan M (2001) In vitro degradation and release profiles for poly-dl-lactide-poly(ethylene glycol) microspheres containing human serum albumin. J Control Release 71(2):165–173PubMedGoogle Scholar
  53. 53.
    Diaz RV, Llabres M, Evora C (1999) One-month sustained release microspheres of 125I-bovine calcitonin. In vitro-in vivo studies. J Control Release 59(1):55–62PubMedGoogle Scholar
  54. 54.
    Dong CM, Guo YZ, Qiu KY, Gu ZW, Feng XD (2005) In vitro degradation and controlled release behavior of D, L-PLGA50 and PCL-b-D, L-PLGA50 copolymer microspheres. J Control Release 107(1):53–64PubMedGoogle Scholar
  55. 55.
    Giammona G, Pitarresi G, Tomarchio V, De Guidi G, Giuffrida S (1998) Swellable microparticles containing Suprofen: evaluation of in vitro release and photochemical behaviour. J Control Release 51(2–3):249–257PubMedGoogle Scholar
  56. 56.
    Jackson JK, Hung T, Letchford K, Burt HM (2007) The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers. Int J Pharm 342(1–2):6–17PubMedGoogle Scholar
  57. 57.
    Liu FI, Kuo JH, Sung KC, Hu OY (2003) Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. Int J Pharm 257(1–2):23–31PubMedGoogle Scholar
  58. 58.
    Liu WH, Song JL, Liu K, Chu DF, Li YX (2005) Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer’s disease. J Control Release 107(3):417–427PubMedGoogle Scholar
  59. 59.
    Lu J, Jackson JK, Gleave ME, Burt HM (2008) The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother Pharmacol 61(6):997–1005PubMedGoogle Scholar
  60. 60.
    Murty SB, Goodman J, Thanoo BC, DeLuca PP (2003) Identification of chemically modified peptide from poly(d,l-lactide-co-glycolide) microspheres under in vitro release conditions. AAPS PharmSciTech 4(4):E50PubMedGoogle Scholar
  61. 61.
    Schaefer MJ, Singh J (2002) Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres. Biomaterials 23(16):3465–3471PubMedGoogle Scholar
  62. 62.
    Yen SY, Sung KC, Wang JJ, Yoa-Pu Hu O (2001) Controlled release of nalbuphine propionate from biodegradable microspheres: in vitro and in vivo studies. Int J Pharm 220(1–2):91–99PubMedGoogle Scholar
  63. 63.
    Latha MS, Lal AV, Kumary TV, Sreekumar R, Jayakrishnan A (2000) Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro studies and in vivo response in rabbits. Contraception 61(5):329–334PubMedGoogle Scholar
  64. 64.
    Negrin CM, Delgado A, Llabres M, Evora C (2001) In vivo-in vitro study of biodegradable methadone delivery systems. Biomaterials 22(6):563–570PubMedGoogle Scholar
  65. 65.
    Park TG, Yong Lee H, Sung Nam Y (1998) A new preparation method for protein loaded poly(d,l-lactic-co-glycolic acid) microspheres and protein release mechanism study. J Control Release 55(2–3):181–191PubMedGoogle Scholar
  66. 66.
    Bodmeier R, McGinity JW (1987) Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. II. Some process parameters influencing the preparation and properties of microspheres. J Microencapsul 4(4):289–297PubMedGoogle Scholar
  67. 67.
    Bodmeier R, McGinity JW (1987) The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method. Pharm Res 4(6):465–471PubMedGoogle Scholar
  68. 68.
    Hatzi P, Mourtas S, Klepetsanis PG, Antimisiaris SG (2007) Integrity of liposomes in presence of cyclodextrins: effect of liposome type and lipid composition. Int J Pharm 333(1–2):167–176PubMedGoogle Scholar
  69. 69.
    Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S (2009) The science of USP 1 and 2 dissolution: present challenges and future relevance. Pharm Res 26(6):1289–1302PubMedGoogle Scholar
  70. 70.
    Aubert-Pouessel A, Venier-Julienne MC, Clavreul A, Sergent M, Jollivet C, Montero-Menei CN, Garcion E, Bibby DC, Menei P, Benoit JP (2004) In vitro study of GDNF release from biodegradable PLGA microspheres. J Control Release 95(3):463–475PubMedGoogle Scholar
  71. 71.
    Balasubramaniam J, Srinatha A, Pandit JK (2008) Studies on indomethacin intraocular implants using different in vitro release methods. Indian J Pharm Sci 70(2):216–221PubMedGoogle Scholar
  72. 72.
    Iyer SS, Barr WH, Dance ME, Coleman PR, Karnes HT (2007) A ‘biorelevant’ system to investigate in vitro drug released from a naltrexone implant. Int J Pharm 340(1–2):104–118PubMedGoogle Scholar
  73. 73.
    Mallarde D, Boutignon F, Moine F, Barre E, David S, Touchet H, Ferruti P, Deghenghi R (2003) PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release. Int J Pharm 261(1–2):69–80PubMedGoogle Scholar
  74. 74.
    Seidlitz A, Nagel S, Semmling B, Grabow N, Martin H, Senz V, Harder C, Sternberg K, Schmitz KP, Kroemer HK, Weitschies W (2010) Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flow-through cell. Eur J Pharm Biopharm 78(1):36–48PubMedGoogle Scholar
  75. 75.
    USP (2010a) <711> Dissolution. The United States Pharmacopeia and National Formularity USP 33–NF 28. Rockville, MDGoogle Scholar
  76. 76.
    Zolnik BS, Burgess DJ (2008) Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 127(2):137–145PubMedGoogle Scholar
  77. 77.
    Zolnik BS, Leary PE, Burgess DJ (2006) Elevated temperature accelerated release testing of PLGA microspheres. J Control Release 112(3):293–300PubMedGoogle Scholar
  78. 78.
    Zolnik BS, Raton J-L, Burgess DJ (2005) Application of USP Apparatus 4 and in situ fiber optic analysis to microsphere release testing. Dissolut TechnolGoogle Scholar
  79. 79.
    Aubert-Pouessel A, Bibby DC, Venier-Julienne MC, Hindre F, Benoit JP (2002) A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres. Pharm Res 19(7):1046–1051PubMedGoogle Scholar
  80. 80.
    Longo WE, Goldberg EP (1985) Hydrophilic albumin microspheres. Methods Enzymol 112:18–26PubMedGoogle Scholar
  81. 81.
    Martinez M, Rathbone M, Burgess D, Huynh M (2008) In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 129(2):79–87PubMedGoogle Scholar
  82. 82.
    Rathbone MJ, Martinez MN, Huynh M, Burgess DJ (2008) CRS/AAPS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained-release products. J Control Release 142(1):2–7Google Scholar
  83. 83.
    Rawat A, Erika S, Shah VP, Burgess DJ (2011) Validation of USP apparatus 4 method for microsphere in vitro release testing. Int J Pharm 409(1–2):178–184PubMedGoogle Scholar
  84. 84.
    Chidambaram N, Burgess DJ (1999) A novel in vitro release method for submicron sized dispersed systems. AAPS PharmSci 1(3):E11PubMedGoogle Scholar
  85. 85.
    Forrest ML, Won CY, Malick AW, Kwon GS (2006) In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J Control Release 110(2):370–377PubMedGoogle Scholar
  86. 86.
    Howze JM, Billups NF (1966) Drug release from ointment bases: characteristics, measurement, and evaluation. II. Dialysis cell method. Am J Pharm Sci Support Public Health 138(5):193–203PubMedGoogle Scholar
  87. 87.
    Kostanski JW, DeLuca PP (2000) A novel in vitro release technique for peptide containing biodegradable microspheres. AAPS PharmSciTech 1(1):E4PubMedGoogle Scholar
  88. 88.
    Lewis KJ, Irwin WJ, Akhtar S (1998) Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro. J Drug Target 5(4):291–302PubMedGoogle Scholar
  89. 89.
    Ma L, Liu M, Liu H, Chen J, Cui D (2010) In vitro cytotoxicity and drug release properties of pH- and temperature-sensitive core-shell hydrogel microspheres. Int J Pharm 385(1–2):86–91PubMedGoogle Scholar
  90. 90.
    Shabbits JA, Chiu GN, Mayer LD (2002) Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release 84(3):161–170PubMedGoogle Scholar
  91. 91.
    Zhou YX, Li SL, Fu HL, Cheng SX, Zhang XZ, Zhuo RX (2008) Fabrication and in vitro drug release study of microsphere drug delivery systems based on amphiphilic poly-alpha, beta-[N-(2-hydroxyethyl)-l-aspartamide]-g-poly(l-lactide) graft copolymers. Colloids Surf B Biointerfaces 61(2):164–169PubMedGoogle Scholar
  92. 92.
    Zhuo RX, Du B, Lu ZR (1999) In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J Control Release 57(3):249–257PubMedGoogle Scholar
  93. 93.
    Schultz K, Mollgaard B, Frokjaer S, Larsen C (1997) Rotating dialysis cell as in vitro release method for oily parenteral depot solutions. Int J Pharm 157(2):163–169PubMedGoogle Scholar
  94. 94.
    Yamazaki M, Itoh S, Sasaki N, Tanabe K, Uchiyama M (1993) Modification of the dialysis membrane method for drug release from suppositories. Pharm Res 10(6):927–929PubMedGoogle Scholar
  95. 95.
    Burgess DJ, Crommelin DJ, Hussain AS, Chen ML (2004) Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci 6(1):E11PubMedGoogle Scholar
  96. 96.
    Burgess DJ, Hussain AS, Ingallinera TS, Chen ML (2002) Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci 4(2):E7PubMedGoogle Scholar
  97. 97.
    Nastruzzi C, Esposito E, Cortesi R, Gambari R, Menegatti E (1994) Kinetics of bromocriptine release from microspheres: comparative analysis between different in vitro models. J Microencapsul 11(5):565–574PubMedGoogle Scholar
  98. 98.
    Abdel-Mottaleb MM, Lamprecht A (2011) Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I. Drug Dev Ind Pharm 37(2):178–184PubMedGoogle Scholar
  99. 99.
    Baxter JL, Kukura J, Muzzio FJ (2005) Shear-induced variability in the United States pharmacopeia apparatus 2: modifications to the existing system. AAPS J 7(4):E857–E864Google Scholar
  100. 100.
    USP (2010b) <724> Drug release. The United States Pharmacopeia and National Formularity USP 33–NF 28Google Scholar
  101. 101.
    Al-Hindawi MK, James KC, Nicholls PJ (1987) Influence of solvent on the availability of testosterone propionate from oily, intramuscular injections in the rat. J Pharm Pharmacol 39(2):90–95PubMedGoogle Scholar
  102. 102.
    Dreyfuss J, Ross JJ Jr, Shaw JM, Miller I, Schreiber EC (1976) Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs. J Pharm Sci 65(4):502–507PubMedGoogle Scholar
  103. 103.
    Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10(4):315–333PubMedGoogle Scholar
  104. 104.
    Kakemi K, Sezaki H, Muranishi S, Ogata H, Giga K (1972) Mechanism of intestinal absorption of drugs from oil in water emulsions. II. Absorption from oily solutions. Chem Pharm Bull (Tokyo) 20(4):715–720Google Scholar
  105. 105.
    Larsen DB, Parshad H, Fredholt K, Larsen C (2002) Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. Int J Pharm 232(1–2):107–117PubMedGoogle Scholar
  106. 106.
    Larsen SW, Frost AB, Ostergaard J, Marcher H, Larsen C (2008) On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds. Eur J Pharm Sci 34(1):37–44PubMedGoogle Scholar
  107. 107.
    Larsen SW, Ostergaard J, Friberg-Johansen H, Jessen MN, Larsen C (2006) In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur J Pharm Sci 29(5):348–354PubMedGoogle Scholar
  108. 108.
    Luo JP, Hubbard JW, Midha KK (1998) The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats. Pharm Res 15(9):1485–1489PubMedGoogle Scholar
  109. 109.
    Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ (1997) Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther 281(1):93–102PubMedGoogle Scholar
  110. 110.
    Radd BL, Newman AC, Fegely BJ, Chrzanowski FA, Lichten JL, Walkling WD (1985) Development of haloperidol in oil injection formulations. J Parenter Sci Technol 39(1):48–51PubMedGoogle Scholar
  111. 111.
    Soderberg L, Dyhre H, Roth B, Bjorkman S (2002) In-vitro release of bupivacaine from injectable lipid formulations investigated by a single drop technique–relation to duration of action in-vivo. J Pharm Pharmacol 54(6):747–755PubMedGoogle Scholar
  112. 112.
    Soderberg L, Dyhre H, Roth B, Bjorkman S (2006) The “inverted cup” – a novel in vitro release technique for drugs in lipid formulations. J Control Release 113(1):80–88PubMedGoogle Scholar
  113. 113.
    Weng Larsen S, Larsen C (2009) Critical factors influencing the in vivo performance of long acting lipophilic solutions–impact on in vitro release method design. AAPS J 11(4):762–770PubMedGoogle Scholar
  114. 114.
    FDA (1997) Dissolution testing of immediate release solid oral dosage forms. Food and Drug Administration Center for Drug Evaluation and Research Guidance for IndustryGoogle Scholar
  115. 115.
    Moore J, Flanner HH (1996) Mathematical comparison of dissolution profiles. Pharm Tech 20:64–74Google Scholar
  116. 116.
    Sathe PM, Tsong Y, Shah VP (1996) In-vitro dissolution profile comparison: statistics and analysis, model dependent approach. Pharm Res 13(12):1799–1803PubMedGoogle Scholar
  117. 117.
    EMEA (1999) NfG on quality of modified release productsGoogle Scholar
  118. 118.
    Emami J (2006) In vitro–in vivo correlation: from theory to applications. J Pharm Pharm Sci 9(2):169–189PubMedGoogle Scholar
  119. 119.
    Schliecker G, Schmidt C, Fuchs S, Ehinger A, Sandow J, Kissel T (2004) In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J Control Release 94(1):25–37PubMedGoogle Scholar
  120. 120.
    Brendel E (2008) BCS-based biowaivers – unresolved issues summary/conclusions of session II. In: EUFEPS network conference 2008 on new regulations in bioequivalence: revised European CHMP note for guidanceGoogle Scholar
  121. 121.
    Chu DF, Fu XQ, Liu WH, Liu K, Li YX (2006) Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 325(1–2):116–123PubMedGoogle Scholar
  122. 122.
    Kim TK, Burgess DJ (2002) Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J Pharm Pharmacol 54(7):897–905PubMedGoogle Scholar
  123. 123.
    Sirisuth N, Eddington ND (2002) The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. Eur J Pharm Biopharm 53(3):301–309PubMedGoogle Scholar

Copyright information

© Controlled Release Society 2012

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, School of PharmacyUniversity of ConnecticutStorrsUSA

Personalised recommendations